REGN 241129 817.50P (REGN241129P817500) Stock Options, News & Quotes

US OptionsDetailed Quotes

REGN241129P817500

Watchlist

18.52
0.000.00%

15min DelayTrading Nov 13 13:51 ET

0.00High0.00Low

Intraday

5D
Daily

News

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
MT Newswires11:02 ET
S&P 500, Dow Hit Records Right After Open | Live Stock
Kevin TraversNov 25 10:00 ET
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Moomoo NewsNov 25 07:31 ET · Ratings
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Moomoo NewsNov 25 06:33 ET · Ratings
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 15% CAGR Over the Last Five Years
Yahoo FinanceNov 23 09:00 ET
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Seeking AlphaNov 23 08:26 ET

Comments

韭菜变主力

2 hours ago

$Regeneron Pharmaceuticals (REGN.US)$ Bought at 743, see how it goes.

NathanRobert

Nov 13 15:03

5 Quality Stocks That Are Undervalued

🔥 We go over 5 stocks that look undervalued, i show you the numbers for yourself, i own 1 of the stocks on the list, but i try to go over stocks you’ve probably never heard of before! LMK ur thoughts :)
$Hershey (HSY.US)$ $Celsius Holdings (CELH.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Yelp Inc (YELP.US)$ $Innovative Industrial Properties Inc (IIPR.US)$

https://youtu.be/4qd-58cBqi4

From YouTube

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Meltyy

Sep 25 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...